Quest Diagnostics Incorporated (DGX) Stock Competitors & Peer Comparison
See (DGX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DGX | $204.53 | +3.71% | 22.6B | 22.60 | $9.05 | +1.60% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.74% |
| TMO | $494.07 | +5.20% | 183.6B | 27.18 | $18.18 | +0.37% |
| DHR | $188.44 | +2.68% | 133.4B | 36.52 | $5.16 | +0.74% |
| IDXX | $578.89 | +3.16% | 45.7B | 42.57 | $13.60 | N/A |
| A | $135.48 | +2.10% | 38.3B | 27.20 | $4.98 | +0.57% |
| NTRA | $222.82 | +4.38% | 31.9B | -137.54 | -$1.62 | N/A |
| IQV | $186.25 | +1.39% | 31.1B | 22.82 | $8.16 | N/A |
| ILMN | $160.03 | +1.26% | 24.2B | 29.10 | $5.50 | N/A |
| WAT | $371.15 | +2.15% | 24.2B | 47.16 | $7.87 | N/A |
Stock Comparison
DGX vs DHR-PB Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, DGX is priced at $204.53, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, DGX's ROE is +0.14%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, DGX is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check DHR-PB's competition here
DGX vs TMO Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, TMO has a market cap of 183.6B. Regarding current trading prices, DGX is priced at $204.53, while TMO trades at $494.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas TMO's P/E ratio is 27.18. In terms of profitability, DGX's ROE is +0.14%, compared to TMO's ROE of +0.13%. Regarding short-term risk, DGX is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check TMO's competition here
DGX vs DHR Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, DHR has a market cap of 133.4B. Regarding current trading prices, DGX is priced at $204.53, while DHR trades at $188.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas DHR's P/E ratio is 36.52. In terms of profitability, DGX's ROE is +0.14%, compared to DHR's ROE of +0.07%. Regarding short-term risk, DGX is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check DHR's competition here
DGX vs IDXX Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, IDXX has a market cap of 45.7B. Regarding current trading prices, DGX is priced at $204.53, while IDXX trades at $578.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas IDXX's P/E ratio is 42.57. In terms of profitability, DGX's ROE is +0.14%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, DGX is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check IDXX's competition here
DGX vs A Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, A has a market cap of 38.3B. Regarding current trading prices, DGX is priced at $204.53, while A trades at $135.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas A's P/E ratio is 27.20. In terms of profitability, DGX's ROE is +0.14%, compared to A's ROE of +0.21%. Regarding short-term risk, DGX is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check A's competition here
DGX vs NTRA Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NTRA has a market cap of 31.9B. Regarding current trading prices, DGX is priced at $204.53, while NTRA trades at $222.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NTRA's P/E ratio is -137.54. In terms of profitability, DGX's ROE is +0.14%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, DGX is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NTRA's competition here
DGX vs IQV Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, IQV has a market cap of 31.1B. Regarding current trading prices, DGX is priced at $204.53, while IQV trades at $186.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas IQV's P/E ratio is 22.82. In terms of profitability, DGX's ROE is +0.14%, compared to IQV's ROE of +0.22%. Regarding short-term risk, DGX is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check IQV's competition here
DGX vs ILMN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ILMN has a market cap of 24.2B. Regarding current trading prices, DGX is priced at $204.53, while ILMN trades at $160.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ILMN's P/E ratio is 29.10. In terms of profitability, DGX's ROE is +0.14%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, DGX is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check ILMN's competition here
DGX vs WAT Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, WAT has a market cap of 24.2B. Regarding current trading prices, DGX is priced at $204.53, while WAT trades at $371.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas WAT's P/E ratio is 47.16. In terms of profitability, DGX's ROE is +0.14%, compared to WAT's ROE of +0.08%. Regarding short-term risk, DGX is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check WAT's competition here
DGX vs MTD Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MTD has a market cap of 23.5B. Regarding current trading prices, DGX is priced at $204.53, while MTD trades at $1,162.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MTD's P/E ratio is 27.30. In terms of profitability, DGX's ROE is +0.14%, compared to MTD's ROE of -6.10%. Regarding short-term risk, DGX is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check MTD's competition here
DGX vs LH Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, LH has a market cap of 22.2B. Regarding current trading prices, DGX is priced at $204.53, while LH trades at $271.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas LH's P/E ratio is 24.02. In terms of profitability, DGX's ROE is +0.14%, compared to LH's ROE of +0.11%. Regarding short-term risk, DGX is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check LH's competition here
DGX vs EXAS Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, DGX is priced at $204.53, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas EXAS's P/E ratio is -95.37. In terms of profitability, DGX's ROE is +0.14%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, DGX is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check EXAS's competition here
DGX vs GH Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, GH has a market cap of 17.3B. Regarding current trading prices, DGX is priced at $204.53, while GH trades at $130.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas GH's P/E ratio is -38.27. In terms of profitability, DGX's ROE is +0.14%, compared to GH's ROE of +1.84%. Regarding short-term risk, DGX is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check GH's competition here
DGX vs ILMNV Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, DGX is priced at $204.53, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ILMNV's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to ILMNV's ROE of N/A. Regarding short-term risk, DGX is more volatile compared to ILMNV. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check ILMNV's competition here
DGX vs PKI Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, DGX is priced at $204.53, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PKI's P/E ratio is 41.45. In terms of profitability, DGX's ROE is +0.14%, compared to PKI's ROE of +0.03%. Regarding short-term risk, DGX is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check PKI's competition here
DGX vs MEDP Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MEDP has a market cap of 13.3B. Regarding current trading prices, DGX is priced at $204.53, while MEDP trades at $466.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MEDP's P/E ratio is 29.38. In terms of profitability, DGX's ROE is +0.14%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, DGX is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check MEDP's competition here
DGX vs ICLR Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ICLR has a market cap of 11.6B. Regarding current trading prices, DGX is priced at $204.53, while ICLR trades at $151.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ICLR's P/E ratio is 52.53. In terms of profitability, DGX's ROE is +0.14%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, DGX is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check ICLR's competition here
DGX vs RVTY Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, RVTY has a market cap of 11.6B. Regarding current trading prices, DGX is priced at $204.53, while RVTY trades at $104.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas RVTY's P/E ratio is 50.06. In terms of profitability, DGX's ROE is +0.14%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, DGX is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check RVTY's competition here
DGX vs CRL Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CRL has a market cap of 9.1B. Regarding current trading prices, DGX is priced at $204.53, while CRL trades at $189.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CRL's P/E ratio is -51.17. In terms of profitability, DGX's ROE is +0.14%, compared to CRL's ROE of -0.06%. Regarding short-term risk, DGX is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check CRL's competition here
DGX vs QGEN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, QGEN has a market cap of 7.8B. Regarding current trading prices, DGX is priced at $204.53, while QGEN trades at $37.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas QGEN's P/E ratio is 19.26. In terms of profitability, DGX's ROE is +0.14%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, DGX is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check QGEN's competition here
DGX vs SHC Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, SHC has a market cap of 4.7B. Regarding current trading prices, DGX is priced at $204.53, while SHC trades at $16.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas SHC's P/E ratio is 40.32. In terms of profitability, DGX's ROE is +0.14%, compared to SHC's ROE of +0.21%. Regarding short-term risk, DGX is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check SHC's competition here
DGX vs BLLN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BLLN has a market cap of 4.7B. Regarding current trading prices, DGX is priced at $204.53, while BLLN trades at $102.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BLLN's P/E ratio is 193.19. In terms of profitability, DGX's ROE is +0.14%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, DGX is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BLLN's competition here
DGX vs SYNH Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, DGX is priced at $204.53, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas SYNH's P/E ratio is 61.40. In terms of profitability, DGX's ROE is +0.14%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, DGX is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check SYNH's competition here
DGX vs RDNT Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, RDNT has a market cap of 4.4B. Regarding current trading prices, DGX is priced at $204.53, while RDNT trades at $56.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas RDNT's P/E ratio is -330.47. In terms of profitability, DGX's ROE is +0.14%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, DGX is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check RDNT's competition here
DGX vs TWST Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, TWST has a market cap of 4.4B. Regarding current trading prices, DGX is priced at $204.53, while TWST trades at $70.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas TWST's P/E ratio is -53.08. In terms of profitability, DGX's ROE is +0.14%, compared to TWST's ROE of -0.17%. Regarding short-term risk, DGX is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check TWST's competition here
DGX vs OLK Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, DGX is priced at $204.53, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas OLK's P/E ratio is -96.59. In terms of profitability, DGX's ROE is +0.14%, compared to OLK's ROE of -0.07%. Regarding short-term risk, DGX is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check OLK's competition here
DGX vs GRAL Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, GRAL has a market cap of 2.6B. Regarding current trading prices, DGX is priced at $204.53, while GRAL trades at $60.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas GRAL's P/E ratio is -5.91. In terms of profitability, DGX's ROE is +0.14%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, DGX is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check GRAL's competition here
DGX vs NEOG Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NEOG has a market cap of 2B. Regarding current trading prices, DGX is priced at $204.53, while NEOG trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NEOG's P/E ratio is -3.26. In terms of profitability, DGX's ROE is +0.14%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, DGX is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NEOG's competition here
DGX vs CDNA Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CDNA has a market cap of 1.2B. Regarding current trading prices, DGX is priced at $204.53, while CDNA trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CDNA's P/E ratio is -142.19. In terms of profitability, DGX's ROE is +0.14%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, DGX is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check CDNA's competition here
DGX vs PSNL Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PSNL has a market cap of 865.8M. Regarding current trading prices, DGX is priced at $204.53, while PSNL trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PSNL's P/E ratio is -9.56. In terms of profitability, DGX's ROE is +0.14%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, DGX is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check PSNL's competition here
DGX vs CSTL Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CSTL has a market cap of 639.4M. Regarding current trading prices, DGX is priced at $204.53, while CSTL trades at $21.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CSTL's P/E ratio is -50.19. In terms of profitability, DGX's ROE is +0.14%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, DGX is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check CSTL's competition here
DGX vs GRALV Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, DGX is priced at $204.53, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas GRALV's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to GRALV's ROE of N/A. Regarding short-term risk, DGX is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check GRALV's competition here
DGX vs FLGT Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, FLGT has a market cap of 525.4M. Regarding current trading prices, DGX is priced at $204.53, while FLGT trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas FLGT's P/E ratio is -7.71. In terms of profitability, DGX's ROE is +0.14%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, DGX is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check FLGT's competition here
DGX vs MYGN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MYGN has a market cap of 428.8M. Regarding current trading prices, DGX is priced at $204.53, while MYGN trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MYGN's P/E ratio is -1.05. In terms of profitability, DGX's ROE is +0.14%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, DGX is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check MYGN's competition here
DGX vs CO Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, DGX is priced at $204.53, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CO's P/E ratio is 5.06. In terms of profitability, DGX's ROE is +0.14%, compared to CO's ROE of +0.11%. Regarding short-term risk, DGX is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check CO's competition here
DGX vs PRE Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PRE has a market cap of 355.8M. Regarding current trading prices, DGX is priced at $204.53, while PRE trades at $20.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PRE's P/E ratio is -8.51. In terms of profitability, DGX's ROE is +0.14%, compared to PRE's ROE of -0.36%. Regarding short-term risk, DGX is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check PRE's competition here
DGX vs NEO Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NEO has a market cap of 297.9M. Regarding current trading prices, DGX is priced at $204.53, while NEO trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NEO's P/E ratio is -14.86. In terms of profitability, DGX's ROE is +0.14%, compared to NEO's ROE of -0.12%. Regarding short-term risk, DGX is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NEO's competition here
DGX vs FLDM Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, DGX is priced at $204.53, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas FLDM's P/E ratio is -4.74. In terms of profitability, DGX's ROE is +0.14%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, DGX is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check FLDM's competition here
DGX vs IMDX Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, IMDX has a market cap of 157M. Regarding current trading prices, DGX is priced at $204.53, while IMDX trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas IMDX's P/E ratio is -3.87. In terms of profitability, DGX's ROE is +0.14%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, DGX is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check IMDX's competition here
DGX vs GTH Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, DGX is priced at $204.53, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas GTH's P/E ratio is -1.11. In terms of profitability, DGX's ROE is +0.14%, compared to GTH's ROE of -1.01%. Regarding short-term risk, DGX is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check GTH's competition here
DGX vs BDSX Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BDSX has a market cap of 125M. Regarding current trading prices, DGX is priced at $204.53, while BDSX trades at $15.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BDSX's P/E ratio is -3.88. In terms of profitability, DGX's ROE is +0.14%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, DGX is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BDSX's competition here
DGX vs GENE Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, DGX is priced at $204.53, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas GENE's P/E ratio is -38.25. In terms of profitability, DGX's ROE is +0.14%, compared to GENE's ROE of -1.85%. Regarding short-term risk, DGX is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check GENE's competition here
DGX vs XGN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, XGN has a market cap of 104.1M. Regarding current trading prices, DGX is priced at $204.53, while XGN trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas XGN's P/E ratio is -4.90. In terms of profitability, DGX's ROE is +0.14%, compared to XGN's ROE of -1.14%. Regarding short-term risk, DGX is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check XGN's competition here
DGX vs STIM Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, STIM has a market cap of 86.3M. Regarding current trading prices, DGX is priced at $204.53, while STIM trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas STIM's P/E ratio is -2.30. In terms of profitability, DGX's ROE is +0.14%, compared to STIM's ROE of -1.65%. Regarding short-term risk, DGX is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check STIM's competition here
DGX vs SERA Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, SERA has a market cap of 81.3M. Regarding current trading prices, DGX is priced at $204.53, while SERA trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas SERA's P/E ratio is -3.33. In terms of profitability, DGX's ROE is +0.14%, compared to SERA's ROE of -0.41%. Regarding short-term risk, DGX is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check SERA's competition here
DGX vs ATLN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ATLN has a market cap of 68.1M. Regarding current trading prices, DGX is priced at $204.53, while ATLN trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ATLN's P/E ratio is -0.79. In terms of profitability, DGX's ROE is +0.14%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, DGX is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check ATLN's competition here
DGX vs DRIO Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, DRIO has a market cap of 55.1M. Regarding current trading prices, DGX is priced at $204.53, while DRIO trades at $7.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas DRIO's P/E ratio is -0.89. In terms of profitability, DGX's ROE is +0.14%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, DGX is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check DRIO's competition here
DGX vs STRRP Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, STRRP has a market cap of 42M. Regarding current trading prices, DGX is priced at $204.53, while STRRP trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas STRRP's P/E ratio is -4.86. In terms of profitability, DGX's ROE is +0.14%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, DGX is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check STRRP's competition here
DGX vs PRPO Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PRPO has a market cap of 41.7M. Regarding current trading prices, DGX is priced at $204.53, while PRPO trades at $23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PRPO's P/E ratio is -51.82. In terms of profitability, DGX's ROE is +0.14%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, DGX is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check PRPO's competition here
DGX vs STRR Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, STRR has a market cap of 40.9M. Regarding current trading prices, DGX is priced at $204.53, while STRR trades at $11.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas STRR's P/E ratio is -4.42. In terms of profitability, DGX's ROE is +0.14%, compared to STRR's ROE of -0.14%. Regarding short-term risk, DGX is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check STRR's competition here
DGX vs MDXH Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MDXH has a market cap of 29.2M. Regarding current trading prices, DGX is priced at $204.53, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MDXH's P/E ratio is -0.88. In terms of profitability, DGX's ROE is +0.14%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, DGX is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check MDXH's competition here
DGX vs AKU Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, DGX is priced at $204.53, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas AKU's P/E ratio is -0.13. In terms of profitability, DGX's ROE is +0.14%, compared to AKU's ROE of -5.32%. Regarding short-term risk, DGX is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check AKU's competition here
DGX vs QUCY Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, QUCY has a market cap of 25.5M. Regarding current trading prices, DGX is priced at $204.53, while QUCY trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas QUCY's P/E ratio is -0.09. In terms of profitability, DGX's ROE is +0.14%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, DGX is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check QUCY's competition here
DGX vs CEMI Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, DGX is priced at $204.53, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CEMI's P/E ratio is -0.63. In terms of profitability, DGX's ROE is +0.14%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, DGX is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check CEMI's competition here
DGX vs ENZ Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, DGX is priced at $204.53, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ENZ's P/E ratio is -2.85. In terms of profitability, DGX's ROE is +0.14%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, DGX is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check ENZ's competition here
DGX vs PMD Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, DGX is priced at $204.53, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PMD's P/E ratio is -5.24. In terms of profitability, DGX's ROE is +0.14%, compared to PMD's ROE of -0.32%. Regarding short-term risk, DGX is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check PMD's competition here
DGX vs ME Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, DGX is priced at $204.53, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ME's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.14%, compared to ME's ROE of -7.71%. Regarding short-term risk, DGX is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check ME's competition here
DGX vs MYNZ Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, DGX is priced at $204.53, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, DGX's ROE is +0.14%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, DGX is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check MYNZ's competition here
DGX vs CHEK Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, DGX is priced at $204.53, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CHEK's P/E ratio is -0.43. In terms of profitability, DGX's ROE is +0.14%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, DGX is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check CHEK's competition here
DGX vs CNTG Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, DGX is priced at $204.53, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CNTG's P/E ratio is -0.23. In terms of profitability, DGX's ROE is +0.14%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, DGX is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check CNTG's competition here
DGX vs BNR Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BNR has a market cap of 8.7M. Regarding current trading prices, DGX is priced at $204.53, while BNR trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BNR's P/E ratio is -10.62. In terms of profitability, DGX's ROE is +0.14%, compared to BNR's ROE of -0.10%. Regarding short-term risk, DGX is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BNR's competition here
DGX vs MBAI Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MBAI has a market cap of 8.2M. Regarding current trading prices, DGX is priced at $204.53, while MBAI trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MBAI's P/E ratio is 2.00. In terms of profitability, DGX's ROE is +0.14%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, DGX is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check MBAI's competition here
DGX vs VNRX Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, VNRX has a market cap of 7.3M. Regarding current trading prices, DGX is priced at $204.53, while VNRX trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas VNRX's P/E ratio is -0.32. In terms of profitability, DGX's ROE is +0.14%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, DGX is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check VNRX's competition here
DGX vs APDN Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, DGX is priced at $204.53, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas APDN's P/E ratio is -0.10. In terms of profitability, DGX's ROE is +0.14%, compared to APDN's ROE of -6.53%. Regarding short-term risk, DGX is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check APDN's competition here
DGX vs TRIB Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, TRIB has a market cap of 6.9M. Regarding current trading prices, DGX is priced at $204.53, while TRIB trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas TRIB's P/E ratio is -0.33. In terms of profitability, DGX's ROE is +0.14%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, DGX is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check TRIB's competition here
DGX vs BIAF Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BIAF has a market cap of 6.8M. Regarding current trading prices, DGX is priced at $204.53, while BIAF trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BIAF's P/E ratio is -0.32. In terms of profitability, DGX's ROE is +0.14%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, DGX is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BIAF's competition here
DGX vs NVTA Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, DGX is priced at $204.53, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NVTA's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.14%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, DGX is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NVTA's competition here
DGX vs LMDXW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, DGX is priced at $204.53, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, DGX's ROE is +0.14%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, DGX is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check LMDXW's competition here
DGX vs LMDX Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, DGX is priced at $204.53, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas LMDX's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.14%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, DGX is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check LMDX's competition here
DGX vs BGLC Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BGLC has a market cap of 4.4M. Regarding current trading prices, DGX is priced at $204.53, while BGLC trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BGLC's P/E ratio is -1.46. In terms of profitability, DGX's ROE is +0.14%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, DGX is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check BGLC's competition here
DGX vs ADVB Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ADVB has a market cap of 4M. Regarding current trading prices, DGX is priced at $204.53, while ADVB trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ADVB's P/E ratio is 0.93. In terms of profitability, DGX's ROE is +0.14%, compared to ADVB's ROE of -0.65%. Regarding short-term risk, DGX is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check ADVB's competition here
DGX vs BNGO Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BNGO has a market cap of 3.8M. Regarding current trading prices, DGX is priced at $204.53, while BNGO trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BNGO's P/E ratio is -0.26. In terms of profitability, DGX's ROE is +0.14%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, DGX is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BNGO's competition here
DGX vs NDRA Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NDRA has a market cap of 3.3M. Regarding current trading prices, DGX is priced at $204.53, while NDRA trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NDRA's P/E ratio is -0.54. In terms of profitability, DGX's ROE is +0.14%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, DGX is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NDRA's competition here
DGX vs NOTV Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NOTV has a market cap of 3.3M. Regarding current trading prices, DGX is priced at $204.53, while NOTV trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NOTV's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.14%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, DGX is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NOTV's competition here
DGX vs DMTK Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, DGX is priced at $204.53, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas DMTK's P/E ratio is -0.04. In terms of profitability, DGX's ROE is +0.14%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, DGX is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check DMTK's competition here
DGX vs SQL Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, DGX is priced at $204.53, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas SQL's P/E ratio is -0.40. In terms of profitability, DGX's ROE is +0.14%, compared to SQL's ROE of +2.74%. Regarding short-term risk, DGX is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check SQL's competition here
DGX vs AWH Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, DGX is priced at $204.53, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas AWH's P/E ratio is -0.09. In terms of profitability, DGX's ROE is +0.14%, compared to AWH's ROE of +2.03%. Regarding short-term risk, DGX is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check AWH's competition here
DGX vs INBS Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, DGX is priced at $204.53, while INBS trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas INBS's P/E ratio is -0.21. In terms of profitability, DGX's ROE is +0.14%, compared to INBS's ROE of -1.74%. Regarding short-term risk, DGX is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check INBS's competition here
DGX vs HTGM Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, DGX is priced at $204.53, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas HTGM's P/E ratio is -0.03. In terms of profitability, DGX's ROE is +0.14%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, DGX is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check HTGM's competition here
DGX vs BIAFW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BIAFW has a market cap of 707.6K. Regarding current trading prices, DGX is priced at $204.53, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BIAFW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, DGX is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check BIAFW's competition here
DGX vs BIOC Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, DGX is priced at $204.53, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BIOC's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.14%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, DGX is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BIOC's competition here
DGX vs ISPC Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, ISPC has a market cap of 405.5K. Regarding current trading prices, DGX is priced at $204.53, while ISPC trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas ISPC's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.14%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, DGX is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check ISPC's competition here
DGX vs PRENW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PRENW has a market cap of 184.1K. Regarding current trading prices, DGX is priced at $204.53, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PRENW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, DGX is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check PRENW's competition here
DGX vs SQLLW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, DGX is priced at $204.53, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, DGX's ROE is +0.14%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, DGX is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check SQLLW's competition here
DGX vs NDRAW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas NDRAW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, DGX is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check NDRAW's competition here
DGX vs CHEKZ Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, DGX is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check CHEKZ's competition here
DGX vs MEUSW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas MEUSW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, DGX is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check MEUSW's competition here
DGX vs OCDX Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas OCDX's P/E ratio is -42.28. In terms of profitability, DGX's ROE is +0.14%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, DGX is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check OCDX's competition here
DGX vs PRXL Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas PRXL's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, DGX is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check PRXL's competition here
DGX vs DHR-PA Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, DGX's ROE is +0.14%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, DGX is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for DGX.Check DHR-PA's competition here
DGX vs BNGOW Comparison June 2026
DGX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGX stands at 22.6B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, DGX is priced at $204.53, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGX currently has a P/E ratio of 22.60, whereas BNGOW's P/E ratio is N/A. In terms of profitability, DGX's ROE is +0.14%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, DGX is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for DGX.Check BNGOW's competition here